Towards Predicting Protective Vaccine Responses in the Very Young

Trends in Immunology

Volumn 37, Issue 8, 2016, Pages 523-534

  Kollmann, Tobias R ^a   Marchant, Arnaud ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; MENINGOCOCCUS VACCINE; VACCINE; YELLOW FEVER VACCINE;

AGE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION; INFLUENZA; MENINGOCOCCEMIA; NONHUMAN; PREDICTIVE VALUE; REVIEW; VACCINATION; YELLOW FEVER; ANIMAL; COMMUNICABLE DISEASE CONTROL; CYTOLOGY; IMMUNE SYSTEM; IMMUNITY; IMMUNOLOGY; METABOLISM; OUTCOME ASSESSMENT; PROCEDURES; PROGNOSIS;

AGE FACTORS; ANIMALS; COMMUNICABLE DISEASE CONTROL; HUMANS; IMMUNE SYSTEM; IMMUNITY; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; VACCINATION; VACCINES;

EID: 84991824040     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2016.05.005     Document Type: Review

References (73)

1. 1 Liu, L., et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet 379 (2012), 2151–2161.
2. 2 Bhutta, Z.A., Black, R.E., Global maternal, newborn, and child health – so near and yet so far. N. Engl. J. Med. 369 (2013), 2226–2235.
3. 3 McMorrow, M., Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015. MMWR Morbid. Mortal. Wkly. Rep. 55 (2006), 511–515.
4. 4 Clark, A., Sanderson, C., Timing of children's vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 373 (2009), 1543–1549.
5. 5 World Health Organization, Recommendations for Routine Immunization. 2015, World Health Organization.
6. 6 Levy, O., et al. Immune response to vaccine adjuvants during the first year of life. Vaccine 31 (2013), 2500–2505.
7. 7 Baxter, D., Vaccine responsiveness in premature infants. Hum. Vaccin. 6 (2010), 506–511.
8. 8 Klein Klouwenberg, P., Bont, L., Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines. Clin. Dev. Immunol., 2008, 2008, 628963.
9. 9 Clemens, J., Jodar, L., Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Nat. Med. 11 (2005), S12–S15.
10. 10 Pulendran, B., Systems vaccinology: probing humanity's diverse immune systems with vaccines. Proc. Natl. Acad. Sci. U.S.A. 111 (2014), 12300–12306.
11. 11 Nakaya, H.I., Pulendran, B., Vaccinology in the era of high-throughput biology. Philos. Trans. R. Soc Lond. B Biol. Sci., 370, 2015, 1671.
12. 12 Cortese, M., et al. Translating glycolytic metabolism to innate immunity in dendritic cells. Cell Metab. 19 (2014), 737–739.
13. 13 Oh, J.Z., et al. TLR5-mediated sensing of gut microbiota is necessary for antibody responses to seasonal influenza vaccination. Immunity 41 (2014), 478–492.
14. 14 Huda, M.N., et al. Stool microbiota and vaccine responses of infants. Pediatrics 134 (2014), e362–e372.
15. 15 Vahey, M.T., et al. Expression of genes associated with immunoproteasome processing of major histocompatibility complex peptides is indicative of protection with adjuvanted RTS, S malaria vaccine. J. Infect. Dis. 201 (2010), 580–589.
16. 16 Plotkin, S.A., Complex correlates of protection after vaccination. Clin. Infect. Dis. 56 (2013), 1458–1465.
17. 17 Haining, W.N., Pulendran, B., Identifying gnostic predictors of the vaccine response. Curr. Opin. Immunol. 24 (2012), 332–336.
18. 18 Pulendran, B., Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. 9 (2009), 741–747.
19. 19 David-West, T.S., Concurrent and consecutive infection and immunisation with yellow fever and UGMP-359 viruses. Arch. Virol. 48 (1975), 21–28.
20. 20 Fernandes, C., Randomized, double-blind, multicenter study of the immunogenicity and reactogenicity of 17DD and WHO 17D-213/77 yellow fever vaccines in children: implications for the Brazilian National Immunization Program. Vaccine 25 (2007), 3118–3123.
21. 21 Suzano, C.E., et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 24 (2006), 1421–1426.
22. 22 Yvonnet, B., et al. Simultaneous administration of hepatitis B and yellow fever vaccines. J. Med. Virol. 19 (1986), 307–311.
23. 23 Adu, F.D., et al. Field trial of combined yellow fever and measles vaccines among children in Nigeria. East Afr. Med. J. 73 (1996), 579–582.
24. 24 Nascimento Silva, J.R., et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine 29 (2011), 6327–6334.
25. 25 Campi-Azevedo, A.C., et al. 17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children. PLoS ONE, 7, 2012, e49828.
26. 26 Gaucher, D., et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J. Exp. Med. 205 (2008), 3119–3131.
27. 27 Querec, T.D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 10 (2009), 116–125.
28. 28 Sridhar, S., et al. Influenza vaccination strategies: comparing inactivated and live attenuated influenza vaccines. Vaccines (Basel) 3 (2015), 373–389.
29. 29 Ilyushina, N.A., et al. Live attenuated and inactivated influenza vaccines in children. J. Infect. Dis. 211 (2015), 352–360.
30. 30 Coudeville, L., et al. Relationship between haemagglutination-inhibiting antibody titers and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol., 10, 2010, 18.
31. 31 Black, S., et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr. Infect. Dis. J. 30 (2011), 1081–1085.
32. 32 Bucasas, K.L., et al. Early patterns of gene expression correlate with the humoral immune response to influenza vaccination in humans. J. Infect. Dis. 203 (2011), 921–929.
33. 33 Nakaya, H.I., et al. Systems biology of vaccination for seasonal influenza in humans. Nat. Immunol. 12 (2011), 786–795.
34. 34 Li, S., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat. Immunol. 15 (2014), 195–204.
35. 35 Obermoser, G., et al. Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines. Immunity 38 (2013), 831–844.
36. 36 Tsang, J.S., et al. Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 157 (2014), 499–513.
37. 37 Zhu, W., et al. A whole genome transcriptional analysis of the early immune response induced by live attenuated and inactivated influenza vaccines in young children. Vaccine 28 (2010), 2865–2876.
38. 38 Cao, R.G., et al. Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. J. Infect. Dis. 210 (2014), 224–233.
39. 39 Ali, A., et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog. Glob. Health 108 (2014), 11–20.
40. 40 Borrow, R., et al. Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine 31 (2013), 4477–4486.
41. 41 Garrido-Estepa, M., et al. Meningococcal C conjugate age-dependant long-term loss of effectiveness. Vaccine 33 (2015), 2221–2227.
42. 42 Kollmann, T.R., et al. Innate immune function by toll-like receptors: distinct responses in newborns and the elderly. Immunity 37 (2012), 771–783.
43. 43 Goriely, S., et al. How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. 8 (2008), 81–86.
44. 44 Goriely, S., Goldman, M., Interleukin-12 family members and the balance between rejection and tolerance. Curr. Opin. Organ Transplant. 13 (2008), 4–9.
45. 45 Danis, B., et al. Interferon regulatory factor 7-mediated responses are defective in cord blood plasmacytoid dendritic cells. Eur. J. Immunol. 38 (2008), 507–517.
46. 46 Aksoy, E., et al. Interferon regulatory factor 3-dependent responses to lipopolysaccharide are selectively blunted in cord blood cells. Blood 109 (2007), 2887–2893.
47. 47 Nguyen, M., et al. Acquisition of adult-like TLR4 and TLR9 responses during the first year of life. PLoS ONE, 5, 2010, e10407.
48. 48 Kanswal, S., et al. Deficient TACI expression on B lymphocytes of newborn mice leads to defective Ig secretion in response to BAFF or APRIL. J. Immunol. 181 (2008), 976–990.
49. 49 Kaur, K., et al. Decreased expression of tumor necrosis factor family receptors involved in humoral immune responses in preterm neonates. Blood 110 (2007), 2948–2954.
50. 50 Gardam, S., Brink, R., Non-canonical NF-κB signaling initiated by BAFF influences B cell biology at multiple junctures. Front. Immunol., 4, 2014, 509.
51. 51 Mackay, F., Schneider, P., Cracking the BAFF code. Nat. Rev. Immunol. 9 (2009), 491–502.
52. 52 Gartlehner, G., et al. A simple and valid tool distinguished efficacy from effectiveness studies. J. Clin. Epidemiol. 59 (2006), 1040–1048.
53. 53 Sallusto, F., et al. From vaccines to memory and back. Immunity 33 (2010), 451–463.
54. 54 Initiative for Vaccine Research, World Health Organization. Correlates of Vaccine-Induced Protection: Methods and Implications. 2013, World Health Organization.
55. 55 Iwasaki, A., Medzhitov, R., Control of adaptive immunity by the innate immune system. Nat Immunol 16 (2015), 343–353.
56. 56 Quintin, J., et al. Innate immune memory: towards a better understanding of host defense mechanisms. Curr. Opin. Immunol. 29c (2014), 1–7.
57. 57 Pulendran, B., Ahmed, R., Translating innate immunity into immunological memory: implications for vaccine development. Cell 124 (2006), 849–863.
58. 58 Ferreira, R.B., et al. Should the human microbiome be considered when developing vaccines?. PLoS Pathog., 6, 2010, e1001190.
59. 59 Maidens, C., et al. Modulation of vaccine response by concomitant probiotic administration. Br. J. Clin. Pharmacol. 75 (2013), 663–670.
60. 60 Goenka, A., Kollmann, T.R., Development of immunity in early life. J. Infect. 71:Suppl. 1 (2015), S112–S120.
61. 61 Nakaya, H.I., et al. Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures. Immunity 43 (2015), 1186–1198.
62. 62 Muyanja, E., et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124 (2014), 3147–3158.
63. 63 Kollmann, T.R., Variation between populations in the innate immune response to vaccine adjuvants. Front. Immunol., 4, 2013, 81.
64. 64 Aldrimer, M., et al. Population-based pediatric reference intervals for hematology, iron and transferrin. Scand J. Clin. Lab. Invest. 73 (2013), 253–261.
65. 65 Fourati, S., et al. Pre-vaccination inflammation and B-cell signalling predict age-related hyporesponse to hepatitis B vaccination. Nat. Commun., 7, 2016, 10369.
66. 66 Poland, G.A., et al. Vaccinomics, adversomics, and the immune response network theory: individualized vaccinology in the 21st century. Semin. Immunol. 25 (2013), 89–103.
67. 67 Qin, L., et al. A framework for assessing immunological correlates of protection in vaccine trials. J. Infect. Dis. 196 (2007), 1304–1312.
68. 68 Sadoff, J.C., Wittes, J., Correlates, surrogates, and vaccines. J. Infect. Dis. 196 (2007), 1279–1281.
69. 69 Gradmann, C., A spirit of scientific rigour: Koch's postulates in twentieth-century medicine. Microbes Infect. 16 (2014), 885–892.
70. 70 Darton, T.C., et al. Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infect. Dis. 15 (2015), 840–851.
71. 71 Weinberg, G.A., Szilagyi, P.G., Vaccine epidemiology: efficacy, effectiveness, and the translational research roadmap. J. Infect. Dis. 201 (2010), 1607–1610.
72. 72 Greenwood, M., Yule, G.U., The statistics of anti-typhoid and anti-cholera inoculations, and the interpretation of such statistics in general. J. R. Soc. Med. 8 (Sect. Epidemiol. State Med.) (1915), 113–194.
73. 73 Clemens, J., et al. Evaluating new vaccines for developing countries. Efficacy or effectiveness?. JAMA 275 (1996), 390–397.